Analyst Price Targets — XFOR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 10, 2026 10:22 am | — | Wells Fargo | $11.00 | $3.96 | TheFly | X4 Pharmaceuticals initiated with an Overweight at Wells Fargo |
| June 2, 2026 10:22 am | Thomas Smith | Leerink Partners | $12.00 | $4.11 | TheFly | X4 Pharmaceuticals initiated with an Outperform at Leerink |
| March 9, 2026 10:45 am | — | Guggenheim | $12.00 | $4.15 | TheFly | X4 Pharmaceuticals initiated with a Buy at Guggenheim |
| December 5, 2025 11:37 am | James Condulis | Stifel Nicolaus | $10.00 | $3.80 | TheFly | X4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel |
| November 5, 2025 5:17 pm | Stephen Willey | Stifel Nicolaus | $7.50 | $3.60 | StreetInsider | X4 Pharmaceuticals (XFOR) PT Lowered to $7.50 at Stifel |
| August 29, 2025 11:57 am | Stephen Willey | Stifel Nicolaus | $9.00 | $3.87 | TheFly | X4 Pharmaceuticals price target lowered to $9 from $30 at Stifel |
| August 13, 2025 10:12 am | Swayampakula Ramakanth | H.C. Wainwright | $3.50 | $2.58 | TheFly | X4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright |
| December 22, 2022 6:43 am | — | Cantor Fitzgerald | $3.00 | $0.85 | Benzinga | Cantor Fitzgerald Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $3 |
| December 11, 2022 5:05 pm | Edward Tenthoff | Piper Sandler | $3.00 | $0.93 | TheFly | X4 Pharmaceuticals initiated with an Overweight at Piper Sandler |
| November 30, 2022 6:30 am | — | H.C. Wainwright | $5.00 | $1.85 | Benzinga | HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5 |
Latest News for XFOR
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on August 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”).
X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the second quarter ended June 30, 2026 and provided a corporate update.
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the…
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 6, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XFOR.
U.S. House Trading
No House trades found for XFOR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.